​

Biomea Fusion Stock (NASDAQ:BMEA)

ForecastOwnershipFinancialsChart
Biomea Fusion by TradingView

Previous Close

$1.15

52W Range

$0.87 - $3.08

50D Avg

$1.55

200D Avg

$1.48

Market Cap

$70.80M

Avg Vol (3M)

$1.55M

Beta

-0.33

Div Yield

-

BMEA Company Profile

Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

79

IPO Date

Apr 16, 2021

Website

BMEA Performance

BMEA Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-81.31M$-144.07M$-126.14M
Net Income$-61.80M$-138.43M$-117.25M
EBITDA$-83.51M$-142.32M$-124.62M
Basic EPS$-1.18$-3.83$-3.44
Diluted EPS$-1.18$-3.83$-3.44

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
CAMPCAMP4 Therapeutics Corporation
GUTSFractyl Health, Inc. Common Stock
RPTXRepare Therapeutics Inc.
ALXOALX Oncology Holdings Inc.
PMVPPMV Pharmaceuticals, Inc.
STROSutro Biopharma, Inc.
IMUXImmunic, Inc.
CBUSCibus, Inc.
UNCYUnicycive Therapeutics, Inc.